Page 22 - Recursion Pharmaceuticals News Today

Iambic Therapeutics brings together software engineers and drug-hunting scientists, all sharing the goal of using artificial intelligence to optimize properties of small molecule drugs. The startup will apply its Series B financing to a cancer drug pipeline that includes two candidates on track for the clinic in 2024.

These two next-gen biotechs could be outstanding buys for patient investors.

Yong Rong HK Asset Management Ltd acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The firm acquired 1,174,200 shares of the company’s stock, valued at approximately $8,772,000. Recursion Pharmaceuticals accounts for 3.8% of Yong Rong HK Asset […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott Larson sold 3,000 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $7.72, for a total value of $23,160.00. Following the completion of the sale, the chief operating officer now owns 418,782 […]

Even if you're bullish on AI, you may want to think twice about buying shares of these two companies.

These two cutting-edge healthcare companies could be significantly undervalued right now.

These two cutting-edge healthcare companies could be significantly undervalued right now.

This small-cap stock hopes to revolutionize drug discovery with the help of AI.

Stock markets were in see-saw mode before the Fed’s September decision on rate hikes.

In this article, we will take a look at the 25 biggest stocks with negative beta. To see more such companies, go directly to 5 Biggest Stocks with Negative Beta. Stock markets were in see-saw mode before the Fed’s September decision on rate hikes. Markets gained on September 11 after positive data from China and […]